Clinical Trial Update: Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update explores exenatide administered weekly for two years as a potential disease-modifying treatment for Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: University College, London | Conditions: Parkinson's Disease | Phase 3 | Status: UNKNOWN